This Psychedelics Co. May IPO With '$100M In Revenue,' Changing Mental Health Forever, Says VC Investor

In the evolving narrative of modern medicine, there's a new chapter being written by the pioneers at the helm of Mystic Ventures, where managing partner Jeremy Gardner is intently focused on the profound potential of psychedelics. The latest developments in this arena are not just about a burgeoning industry, but a seismic shift in how we approach some of the most intractable mental health issues.

"There's never been a more exciting time to be doing what we're doing," Gardner states, his voice resonating with the kind of conviction that only comes when one's work aligns seamlessly with one's values. At the age of 31, having already navigated multiple careers, Gardner has found his calling in the psychedelic space, an industry at the precipice of a revolution.

Mystic Ventures has strategically chosen to focus on the private markets, where Gardner believes companies can mature adequately without the pressures of public scrutiny. This approach has led them to an organization that stands out not just for its clinical advancements but for its anticipated financial success: the for-profit arm of MAPS, the Multidisciplinary Association for Psychedelic Studies.

As Jeremy explains, "MAPS could be the first drug development company ever to go public after getting FDA approval, and they'll have $100-plus million in revenue when they do go public - while psychedelics companies that are currently public boast no revenue or very small sales." This isn't just another company making its way through the trials and tribulations of FDA approval; this is a trailblazer redefining what a drug development company can be.

MAPS is taking a Schedule I narcotic (MDMA) through the arduous journey of rescheduling and is pioneering a drug treatment that also mandates therapy, a holistic approach rarely (if ever) seen in psychiatry. "They've gone so above and beyond compared to what anyone else is going to have to do," Gardner adds, his admiration for MAPS' tenacity apparent.

But it's not merely about the innovative approach or the clinical trials, it's the staggering results that are impossible to ignore. Gardner cites, "71% of participants in their trials no longer qualified for a PTSD diagnosis after 12 weeks." These numbers aren't just statistics; they represent a monumental leap forward in treating PTSD, an affliction that impacts up to 7% of all Americans during their lifetimes.

Looking ahead, Jeremy envisions the moment MAPS gets FDA approval in the next six months as a turning point. "It's going to be a huge moment in time," he predicts, outlining a future where MAPS isn't just a company going public but a beacon of hope validating the entire psychedelics industry.

A potential IPO in late 2025 or early 2026 isn't just another entry into the stock market. It's poised to be a historical event, marking the culmination of years of research, dedication and an unwavering belief in the power of psychedelics to heal. "It's going to be massive and such validation for this industry," Gardner asserts.

In this conversation, Jeremy Gardner of Mystic Ventures doesn't just offer insight into the promising horizon of psychedelic medicine. He provides a glimpse into a future where the alignment of profit and purpose can catalyze a new era in mental health treatment. For Gardner and the team at Mystic Ventures, it's not only about the success of their investments but also the indubitable positive impact on society at large — a testament to the belief that business can be a force for good.

Image generated with AI.